Diabetes, Gestational

The condition arises from pregnancy-induced insulin resistance combined with an inadequate pancreatic beta-cell response. The literature also supports contributions from placental hormones, genetic and epigenetic factors, obesity, inactivity, and an unhealthy diet. Some reviews also describe altered incretin signaling, inflammatory cytokines, and mitochondrial dysfunction as part of the causal background.

Gestational diabetes is driven by chronic insulin resistance during pregnancy with insufficient compensation by pancreatic beta cells. Reported mechanisms include reduced GLP-1 and GIP signaling, inflammatory impairment of insulin receptor substrate-1 phosphorylation, decreased PDX1 expression, endoplasmic reticulum stress, and mitochondrial dysfunction that reduces glucose-stimulated insulin secretion. Metabolic reprogramming and changes in the gastrointestinal microbiome have also been discussed as relevant to disease biology.

Reported risk factors include overweight and obesity, advanced maternal age, and a family history of diabetes or any form of diabetes. Other factors associated with increased insulin resistance in pregnancy include inactivity, an unhealthy diet, and genetic or epigenetic predisposition. The condition is also more likely in the setting of pregnancy-related hormonal changes that intensify insulin resistance in the second half of gestation.

The supplied material supports management at the level of general modalities rather than specific regimens. Treatment and prevention approaches include insulin-based therapy, dietary management, and laboratory monitoring of glucose-related markers such as glycated hemoglobin. The literature also discusses prevention and control strategies and emerging microbiome-related approaches, but does not provide enough detail here to specify a standard drug-class pathway beyond insulin and glucose management.